Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.33 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.33 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.33 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4076188 | 0.92 | KDM4C (0.42) | KDM4CNPC1RAB9AMEN1KMT2A | |
| SCHEMBL4078729 | 0.91 | KDM4C (0.39) | KDM4CNPC1RAB9AMEN1KMT2A | |
| SCHEMBL16278814 | 0.90 | KDM4C (0.39) | KDM4CNPC1RAB9AMEN1KMT2A | |
| SCHEMBL4079759 | 0.89 | KDM4C (0.40) | KDM4CNPC1RAB9AMEN1KMT2A | |
| SCHEMBL16279038 | 0.89 | ALDH1A1 (0.45) | KDM4CNPC1RAB9AMEN1KMT2A | |
| SCHEMBL17687524 | 0.89 | KDM4C (0.41) | KDM4CNPC1RAB9AMEN1KMT2A | |
| SCHEMBL16280145 | 0.87 | MEN1 (0.39) | KDM4CNPC1RAB9AMEN1KMT2A | |
| SCHEMBL16280188 | 0.87 | L3MBTL1 (0.42) | KDM4CNPC1RAB9AMEN1KMT2A | |
| SCHEMBL15008645 | 0.84 | KDM4C (0.38) | KDM4CNPC1RAB9AMEN1KMT2A | |
| SCHEMBL16284440 | 0.84 | L3MBTL1 (0.38) | KDM4CNPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9527846-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-12-27 | — | — | US | disclosed |
| US-9527846-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-12-27 | — | — | US | disclosed |
| US-9527846-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-12-27 | — | — | US | disclosed |
| EP-2788349-B1 | KINASE INHIBITORS | CHIESI FARMA SPA (IT) | 2016-10-26 | — | — | EP | disclosed |
| EP-2788349-B1 | KINASE INHIBITORS | CHIESI FARMA SPA (IT) | 2016-10-26 | — | — | EP | disclosed |
| EP-2788348-B1 | KINASE INHIBITORS | CHIESI FARMA SPA (IT) | 2016-10-19 | — | — | EP | disclosed |
| EP-2788348-B1 | KINASE INHIBITORS | CHIESI FARMA SPA (IT) | 2016-10-19 | — | — | EP | disclosed |
| US-20160229852-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-08-11 | — | — | US | disclosed |
| US-20160229852-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-08-11 | — | — | US | disclosed |
| US-20160229852-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-08-11 | — | — | US | disclosed |
| US-20090270350-A1 | Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives | PFIZER INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090270350-A1 | Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives | PFIZER INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090239899-A1 | Triazolopyridinylsulfanyl Derivatives As P38 Map Kinase Inhibitors | PFIZER INC. | 2009-09-24 | — | — | US | disclosed |
| EP-1778686-B9 | TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS | PFIZER LTD (GB) | 2009-07-08 | — | — | EP | disclosed |
| US-7511057-B2 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER INC. (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1987022-A1 | PYRIDINONE PYRAZOLE UREA AND PYRIMIDINONE PYRAZOLE UREA DERIVATIVES | Pfizer Products Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| EP-1778686-B1 | TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS | PFIZER LTD (GB) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007091176-A1 | PYRIDINONE PYRAZOLE UREA AND PYRIMIDINONE PYRAZOLE UREA DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007091176-A1 | PYRIDINONE PYRAZOLE UREA AND PYRIMIDINONE PYRAZOLE UREA DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| US-20060035922-A1 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER INC. | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035922-A1 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | MAPK1, MAPKAPK5, MAPKAPK3 | KDM4C 4771/4885NPC1 1088/4885RAB9A 2552/4885 |
| US-20160229852-A1 | KINASE INHIBITORS | MAPK1, MAP3K1, MAPK6 | KDM4C 4488/4885NPC1 3491/4885RAB9A 856/4885 |
| US-20090270350-A1 | Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives | PDXK, UMPS, CDK2 | KDM4C 1262/4885NPC1 4791/4885RAB9A 2377/4885 |
| US-20090239899-A1 | Triazolopyridinylsulfanyl Derivatives As P38 Map Kinase Inhibitors | MAPK1, MAPKAPK5, MAPKAPK3 | KDM4C 4773/4885NPC1 934/4885RAB9A 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.